Equities Analysts Set Expectations for BrainsWay Q2 Earnings

BrainsWay Ltd. (NASDAQ:BWAY) – Stock analysts at Northland Capmk increased their Q2 2025 earnings per share estimates for shares of BrainsWay in a research report issued to clients and investors on Tuesday, May 13th. Northland Capmk analyst C. Byrnes now forecasts that the company will post earnings of $0.03 per share for the quarter, up from their prior estimate of $0.02. The consensus estimate for BrainsWay’s current full-year earnings is $0.08 per share. Northland Capmk also issued estimates for BrainsWay’s Q3 2025 earnings at $0.03 EPS, Q4 2025 earnings at $0.03 EPS, FY2025 earnings at $0.13 EPS and FY2026 earnings at $0.16 EPS.

BrainsWay (NASDAQ:BWAY) last announced its quarterly earnings results on Tuesday, May 13th. The company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.02. BrainsWay had a return on equity of 3.52% and a net margin of 3.88%. The company had revenue of $11.54 million during the quarter, compared to analyst estimates of $11.45 million.

Separately, HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of BrainsWay in a research report on Wednesday, March 12th.

BrainsWay Stock Performance

Shares of BWAY stock opened at $9.91 on Friday. BrainsWay has a 1 year low of $5.13 and a 1 year high of $11.79. The stock has a fifty day moving average of $9.14 and a two-hundred day moving average of $9.71. The firm has a market capitalization of $187.02 million, a PE ratio of 99.11 and a beta of 1.25.

Institutional Trading of BrainsWay

Several institutional investors have recently modified their holdings of the company. Valor Management LLC acquired a new stake in shares of BrainsWay in the fourth quarter valued at $19,838,000. Phoenix Financial Ltd. lifted its holdings in shares of BrainsWay by 100.8% in the fourth quarter. Phoenix Financial Ltd. now owns 482,724 shares of the company’s stock valued at $4,552,000 after buying an additional 242,366 shares during the period. ARK Investment Management LLC lifted its holdings in shares of BrainsWay by 7.3% during the first quarter. ARK Investment Management LLC now owns 188,328 shares of the company’s stock valued at $1,783,000 after purchasing an additional 12,740 shares during the last quarter. MYDA Advisors LLC lifted its holdings in shares of BrainsWay by 100.2% during the fourth quarter. MYDA Advisors LLC now owns 120,100 shares of the company’s stock valued at $1,133,000 after purchasing an additional 60,100 shares during the last quarter. Finally, Two Sigma Investments LP lifted its holdings in shares of BrainsWay by 2.0% during the fourth quarter. Two Sigma Investments LP now owns 92,755 shares of the company’s stock valued at $875,000 after purchasing an additional 1,786 shares during the last quarter. Institutional investors and hedge funds own 30.11% of the company’s stock.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.